Core Viewpoint - Lepu Medical has received approval from the National Medical Products Administration for its self-developed polylactic acid facial filler, marking its entry into the dermatology field and aiming to boost its consumer healthcare business [1] Group 1: Company Developments - Lepu Medical has shifted focus from generic drugs to innovative cardiovascular drugs and dermatology injection products due to declining performance [1] - The company reported a significant decline in revenue and net profit, with 2023 revenue at 7.98 billion yuan, down 24.78%, and net profit at 1.26 billion yuan, down 42.91% [5] - In 2024, Lepu Medical's revenue further decreased to 6.103 billion yuan, a 23.52% decline, and net profit dropped to 247 million yuan, down 80.37% [5] - The company has also expanded its product line in dermatology with several injection products, including sodium hyaluronate solutions [4] Group 2: Market Competition - The global market for facial fillers, known as "童颜针," is projected to reach approximately $1.488 billion in 2024, growing to $1.5445 billion in 2025, with a compound annual growth rate of 3.8% from 2025 to 2033 [2] - The domestic market for "童颜针" is expected to exceed 3 billion yuan by 2024, up from about 100 million yuan in 2021 [2] - Competition in the "童颜针" market is intensifying, with six other products already approved prior to Lepu Medical's entry, including both domestic and imported options [2] Group 3: Financial Performance and Future Outlook - Lepu Medical's first quarter of 2025 continued the trend of declining performance, with revenue of 1.736 billion yuan, down 9.67%, and net profit of 379 million yuan, down 21.44% [6] - The company anticipates future profit growth primarily from structural heart disease, dermatology, and neuro-regulation sectors, while traditional medical device products are expected to maintain around 10% revenue growth [6] - The impact of the newly approved dermatology product on Lepu Medical's future performance remains uncertain [3]

Core Viewpoint - Lepu Medical, a leader in cardiovascular devices, has officially entered the dermatology field with the approval of its self-developed polylactic acid facial filler, "童颜针" (Tongyan Needle), marking a significant milestone for the company amid declining performance in recent years [1][5][6]. Company Developments - The "童颜针" is a dermal filler designed to correct moderate to severe nasolabial folds, utilizing polylactic acid (PLLA) which is biodegradable and safe for human use [5][6]. - The product's approval is seen as a key event for Lepu Medical, enhancing its consumer healthcare business and providing new options for both doctors and consumers [5][6]. - The company has been actively expanding into the ophthalmology and dermatology sectors, with several products in various stages of development, including hyaluronic acid gels [5][7]. Financial Performance - Lepu Medical's financial performance has deteriorated significantly, with a projected net profit decline of over 80% in 2024, marking the worst performance since its listing in 2009 [1][7]. - In 2023, the company reported a revenue of approximately 79.8 billion yuan, a year-on-year decrease of 24.78%, and a net profit of about 12.58 billion yuan, down 42.91% [7]. - For 2024, the expected revenue is around 61.03 billion yuan, a decline of 23.52%, with a net profit of approximately 2.47 billion yuan [7][8]. R&D and Market Position - Despite a decline in R&D expenses and personnel, the proportion of R&D investment relative to revenue has increased, indicating a strategic focus on innovation [9][10]. - The number of R&D personnel decreased by over 20% from 2023 to 2024, reflecting potential adjustments in the company's strategic direction [9][10]. - The competitive landscape for the "童颜针" market is intensifying, with seven similar products already approved in China, suggesting a need for Lepu Medical to leverage its technological advantages to stand out [6][7].

Core Viewpoint - Lepu Medical has received NMPA approval for its self-developed polylactic acid facial filler, marking a significant entry into the aesthetic medicine sector amidst intense competition [1][2][3] Group 1: Product Details - The polylactic acid facial filler is classified as a Class III medical device, designed for injection into the dermis to correct moderate to severe nasolabial folds [1] - The main component, polylactic acid (PLLA), is a biodegradable material that is safe and compatible with the human body, breaking down into carbon dioxide and water [2] - The product is expected to provide a new option for doctors and consumers, with good therapeutic effects and low incidence of side effects [5] Group 2: Market Context - The aesthetic medicine market is becoming increasingly competitive, with several companies, including East China Pharmaceutical and Aimeike, already established in the regenerative aesthetic injection sector [2] - The regenerative anti-aging injection market has seen rapid growth, with its market share increasing from 3% in 2019 to 19% in 2023, and projected to reach 31% by 2028 [5][6] Group 3: Strategic Focus - Lepu Medical's entry into the aesthetic medicine field is part of its ongoing strategy to diversify into consumer healthcare and seek new growth avenues [3] - The company aims to mitigate the impact of domestic medical industry policy changes by actively developing self-funded medical products [3] - The strategic focus is on ophthalmology and dermatology, with expectations for a peak in approvals for injectable products in dermatology by 2025 [3][4] Group 4: Financial Impact - The approval of the polylactic acid facial filler is seen as a milestone for Lepu Medical in the dermatology field, potentially driving future business growth [5] - The company reported a revenue of 6.103 billion yuan in 2024, a decline of 23.52% year-on-year, and a net profit of 247 million yuan, down 80.37% year-on-year [3]

证券研究报告——晨会聚焦 2025 年 5 月 7 日 | 5 月金股组合 | | | --- | --- | | 股票代码 | 股票名称 | | 002352.SZ | 顺丰控股 | | 1519.HK | 极兔速递-W | | 603181.SH | 皇马科技 | | 300014.SZ | 亿纬锂能 | | 688198.SH | 佰仁医疗 | | 000524.SZ | 岭南控股 | | 600519.SH | 贵州茅台 | | 9660.HK | 地平线机器人-W | | 688519.SH | 南亚新材 | | 301236.SZ | 软通动力 | 中银晨会聚焦-20250507 ■重点关注 【宏观经济】4 月 PMI 数据点评*陈琦 朱启兵。外部环境对制造企业生产 意愿有所影响。4 月高技术制造业、设备制造业海外需求下滑较为明显。4 月建筑业生产经营延续活跃。部分原材料加工业及纺织工业景气度处于扩 张区间。 【医药生物】键凯科技*刘恩阳。公司公布 24 年年报及 25 年一季报。24 年 全年实现营业收入 2.27 亿元，同比下滑 22.26%，归母净利润为 0.30 亿元， 同比下滑 74.2 ...

原评级：买入 市场价格:人民币 61.00 板块评级:强于大市 股价表现 医药生物 | 证券研究报告 — 调整盈利预测 2025 年 5 月 6 日 688356.SH 买入 中银国际证券股份有限公司 具备证券投资咨询业务资格 医药生物：化学制药 证券分析师：刘恩阳 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 9.9 3.1 22.7 (23.8) 相对上证综指 9.3 5.3 21.9 (29.4) 发行股数 (百万) 60.65 流通股 (百万) 60.65 总市值 (人民币 百万) 3,699.69 3 个月日均交易额 (人民币 百万) 46.76 主要股东持股比例（%） (46%) (35%) (23%) (12%) (0%) 11% May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 键凯科技 上证综指 XUAN ZHAO 24.54 enyang.liu@bocichina.com 证券投资咨询业务证书编号：S1300523090004 资料来源：公司公告， Wind ...